NR at MA

Download as docx, pdf, or txt
Download as docx, pdf, or txt
You are on page 1of 4

Salbutamol HIVENT

NR
1. Assess lung sounds, PR and BP before drug administration and during peak of
medication.
2. Observe fore paradoxical spasm and withhold medication and notify physician if
condition occurs.
3. Administer PO medications with meals to minimize gastric irritation.
4. Extended-release tablet should be swallowed-whole. It should not be crushed or chewed.
5. If administering medication through inhalation, allow at least 1 minute between
inhalation of aerosol medication.
6. Advise the patient to rinse mouth with water after each inhalation to minimize dry mouth.
7. Inform the patient that Albuterol may cause an unusual or bad taste.

MA of Ventrex
It relaxes the smooth muscles of the bronchioles allowing maximum passage of air.
It decreases intracellular calcium which will relax the smooth muscles of the lungs
by mobilizing kinase through activation of cyclic-35-adenosine monophosphate
(cAMP). This high level of cyclic AMP relaxes bronchial smooth muscle and
decreases airway resistance by lowering intracellular ionic calcium concentrations.
Salbutamol relaxes the smooth muscles of airways, from trachea to terminal
bronchioles.

CEFALEXIN- EXEL
MA
Cephalexin, like the penicillins, is a beta-lactam antibiotic. By binding to specific
penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the
third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by
bacterial cell wall autolytic enzymes such as autolysins; it is possible that
cephalexin interferes with an autolysin inhibitor.
- Mechanism of action of cephalexin is similar to penicillin. It acts by inhibiting
bacterial cell wall synthesis, lack of bacterial cell wall results in death due to lysis of
bacteria.

NR

Determine history of hypersensitivity reactions to cephalosporins and penicillin and


history of other drug allergies before therapy is initiated.

Lab tests: Evaluate renal and hepatic function periodically in patients receiving prolonged
therapy.

Monitor for manifestations of hypersensitivity (see Signs & Symptoms, Appendix F).
Discontinue drug and report their appearance promptly.

CEFALEXIN

MONOHYDRATE

NR

Arrange for culture and sensitivity tests of infection before and during therapy if infection
does not resolve.

Give drug with meals; arrange for small, frequent meals if GI complications occur.

Refrigerate suspension, discard after 14 days.

NEOZEP FORTE
NR
Initiate second course of treatment if cure does not occur within 3 wk.
Examine and treat all family members simultaneously because
pinworms are readily
transmitted from person to person.
Practice thorough hand washing after touching any potentially
contaminated item.
Change underclothing, bedclothes, towels, and facecloths daily;
bathe frequently,
preferably by showering. Infected person should sleep alone.
Do not breast feed while taking this drug without consulting
physician.

CARBOCISTINE
NR

. Assess the patient for any history of hypersensitivity or allergy to


Carbocisteine. 2. Special precautions: GI bleeding, pregnancy 3. Special
precaution: history of gastric or duodenal ulcer & GI bleeding. Pregnancy &
lactation. 4. Use with caution in patients with a history of gastric or duodenal
ulcer and gastrointestinal bleeding since mucolytics may disrupt the gastric
mucosal barrier.

BENZYLPENICILLIN

POTASSIUM

NR

Obtain an exact history of patient's previous exposure and sensitivity to penicillins and
cephalosporins and other allergic reactions of any kind prior to treatment with penicillin.

Hypersensitivity reactions are more likely to occur with parenteral penicillin but may also
occur with the oral drug. Skin rash is the most common type allergic reaction and should
be reported promptly to physician.

Lab tests: Perform C&S tests prior to initiation of therapy; treatment may be started
before results are known. Evaluate renal, hepatic, and hematologic systems at regular
intervals in patients on high-dose therapy. Additionally, check electrolyte balance
periodically in patients receiving high parenteral doses.

Observe all patients closely for at least 30 min following administration of parenteral
penicillin. The rapid appearance of a red flare or wheal at the IM or IV injection site is a
possible sign of sensitivity. Also suspect an allergic reaction if patient becomes irritable,
has nausea and vomiting, breathing difficulty, or sudden fever. Report any of the
foregoing to physician immediately.

Be aware that reactions to penicillin may be rapid in onset or may not appear for days or
weeks. Symptoms usually disappear fairly quickly once drug is stopped, but in some
patients may persist for 5 d or more and require hospitalization for treatment.

Allergy to penicillin is unpredictable. It has occurred in patients with a negative history of


penicillin allergy and also in patients with no known prior contact with penicillin
(sensitization may have occurred from penicillin used commercially in foods and
beverages).

Be alert for neuromuscular irritability in patients receiving parenteral penicillin in excess


of 20 million U/d who have renal insufficiency, hyponatremia, or underlying CNS
disease, notably myasthenia gravis or epilepsy. Seizure precautions are indicated.
Symptoms usually begin with twitching, especially of face and extremities.

Monitor I&O, particularly in patients receiving high parenteral doses. Report oliguria,
hematuria, and changes in I&O ratio. Consult physician regarding optimum fluid intake.
Dehydration increases the concentration of drug in kidneys and can cause renal irritation
and damage.

Observe closely for signs of toxicity: Neonates, young infants, the older adult, and
patients with impaired kidney function receiving high-dose penicillin therapy. Urinary
excretion of penicillin is significantly delayed in these patients.

Observe patients on high-dose therapy closely for evidence of bleeding, and bleeding
time should be monitored. (In high doses, penicillin interferes with platelet aggregation.)
MA
By binding to specific penicillin-binding proteins (PBPs) located inside the
bacterial cell wall, penicillin G inhibits the third and last stage of bacterial cell
wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic
enzymes such as autolysins; it is possible that penicillin G interferes with an
autolysin inhibitor.

You might also like